Secondary hypertension

Summary

Secondary hypertension (MONDO:0001200) is a disease and 8 clinical trials. Top therapeutic interventions include lisinopril anhydrous and arginine. A subtype of hypertensive disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	secondary hypertension
Mondo ID	MONDO:0001200
EFO	EFO:1002034
DOID	DOID:11130
ICD-11	1331849426
SNOMED CT	31992008
UMLS	C0155616
MedGen	57609
Is cancer (heuristic)	no

Disease family

This is a subtype of hypertensive disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › hypertensive disorder › secondary hypertension

Related subtypes (11): essential hypertension, pulmonary hypertension, early onset hypertension, chemotherapy-induced hypertension, intracranial hypertension, malignant hypertension, ocular hypertension, kallikrein hypertension, hypertension, pregnancy-induced, resistant hypertension, hypertensive urgency

Subtypes (3): renal hypertension, benign secondary hypertension, malignant secondary hypertension

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02184858	PHASE4	COMPLETED	Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
NCT05925569	Not specified	ACTIVE_NOT_RECRUITING	Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
NCT06228677	Not specified	RECRUITING	Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
NCT07027254	Not specified	RECRUITING	PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
NCT01742702	Not specified	UNKNOWN	HaemoDYNAMICs in Primary and Secondary Hypertension
NCT01854190	Not specified	COMPLETED	Obstructive Sleep Apnea and Endothelial Function in Patients With Resistant Hypertension
NCT06664255	Not specified	COMPLETED	High Prevalence of Secondary Arterial Hypertension (HIPRESH) with Prospective Systematic Screening in a Cohort of Consecutive Hypertensive Patients Referring to Regional Specialized Center
NCT07497841	Not specified	COMPLETED	Development and Validation of a KAP Questionnaire for Secondary Hypertension: Evaluating a Community Short-Video Intervention in Rural Beijing

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LISINOPRIL ANHYDROUS	4	2
ARGININE	3	1